Given that osimertinib is the recommended first-line medication for patients with EGFR-mutated NSCLC according to international guidelines (Piper-Vallillo and Sequist, 2019), vigilance against cardiac QT interval prolongation during treatment is crucial, especially for patients with a history of QT prolongation or concurrent use of other QT interval-prolonging medications (Bian et al., 2020; Maimaitituersun et al., 2023). This evidence concerns the gene EGFR and non-small cell lung carcinoma.